Berberine hydrochloride co-amorphous drug and preparation method thereof
The invention discloses a berberine hydrochloride co-amorphous drug and a preparation method thereof, and the preparation method comprises the following steps: blending berberine hydrochloride and chlorogenic acid, adding into a solvent, grinding, then washing and dissolving by using the solvent, and separating out a solid by using a vacuum rotary evaporation method to obtain the berberine hydrochloride co-amorphous drug. According to the prepared berberine hydrochloride co-amorphous medicine, the solubility of berberine hydrochloride in a 0.1 mol/L HCl buffer solution and water is improved in a co-amorphous mode, and reference is provided for development of oral preparations and external preparations for treating stomach diseases through berberine hydrochloride; the dissolution rate and bioavailability of berberine hydrochloride are improved, and reference is provided for development of a berberine hydrochloride quick-release preparation; in addition, the preparation method disclosed by the invention is simple and easy to implement, mild in condition, easy to control, good in reproducibility, easy to realize large-scale industrial production and low in production cost, and has great commercial application value..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 12. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SHEN XIANGCHUN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-12, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 |
|---|
| Patentnummer: |
CN117379558 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001289527 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001289527 | ||
| 003 | DE-627 | ||
| 005 | 20240329155839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001289527 | ||
| 035 | |a (EPA)CN117379558 | ||
| 035 | |a (EPA)89463150 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SHEN XIANGCHUN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Berberine hydrochloride co-amorphous drug and preparation method thereof |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-12, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 | ||
| 520 | |a The invention discloses a berberine hydrochloride co-amorphous drug and a preparation method thereof, and the preparation method comprises the following steps: blending berberine hydrochloride and chlorogenic acid, adding into a solvent, grinding, then washing and dissolving by using the solvent, and separating out a solid by using a vacuum rotary evaporation method to obtain the berberine hydrochloride co-amorphous drug. According to the prepared berberine hydrochloride co-amorphous medicine, the solubility of berberine hydrochloride in a 0.1 mol/L HCl buffer solution and water is improved in a co-amorphous mode, and reference is provided for development of oral preparations and external preparations for treating stomach diseases through berberine hydrochloride; the dissolution rate and bioavailability of berberine hydrochloride are improved, and reference is provided for development of a berberine hydrochloride quick-release preparation; in addition, the preparation method disclosed by the invention is simple and easy to implement, mild in condition, easy to control, good in reproducibility, easy to realize large-scale industrial production and low in production cost, and has great commercial application value. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a TAO LING |4 aut | |
| 700 | 0 | |a LI JUE |4 aut | |
| 700 | 0 | |a JIANG FEI |4 aut | |
| 700 | 0 | |a CHEN YING |4 aut | |
| 700 | 0 | |a WU XINGJIE |4 aut | |
| 700 | 0 | |a GUO QIANQIAN |4 aut | |
| 700 | 0 | |a LI HUILI |4 aut | |
| 700 | 0 | |a WANG YU'E |4 aut | |
| 700 | 0 | |a YANG JIAJIA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 12. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89463150/publication/CN117379558A1?q=CN117379558 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 01 | ||